GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Price-to-Free-Cash-Flow

Molecular Partners AG (XSWX:MOLN) Price-to-Free-Cash-Flow : N/A (As of May. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Price-to-Free-Cash-Flow?

As of today (2024-05-10), Molecular Partners AG's share price is CHF3.25. Molecular Partners AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-1.83. Hence, Molecular Partners AG's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Molecular Partners AG's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, Molecular Partners AG's highest Price-to-Free-Cash-Flow Ratio was 6.61. The lowest was 1.55. And the median was 1.89.

XSWX:MOLN's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.53
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Molecular Partners AG's Free Cash Flow per Share for the three months ended in Dec. 2023 was CHF-0.50. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was CHF-1.83.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Molecular Partners AG was -151.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -14.10% per year.

During the past 11 years, Molecular Partners AG's highest 3-Year average Free Cash Flow per Share Growth Rate was 56.90% per year. The lowest was -35.70% per year. And the median was -13.70% per year.


Molecular Partners AG Price-to-Free-Cash-Flow Historical Data

The historical data trend for Molecular Partners AG's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Price-to-Free-Cash-Flow Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.75 -

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 - - - -

Competitive Comparison of Molecular Partners AG's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Molecular Partners AG's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Price-to-Free-Cash-Flow falls into.



Molecular Partners AG Price-to-Free-Cash-Flow Calculation

Molecular Partners AG's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.25/-1.825
=N/A

Molecular Partners AG's Share Price of today is CHF3.25.
Molecular Partners AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Molecular Partners AG  (XSWX:MOLN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Molecular Partners AG Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus